ArticleMolecular neurobiology2026
Integrative Transcriptomic, Network, and Machine Learning Analyses Identify Genistein and Resveratrol-Associated Therapeutic Targets in Alzheimer's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by complex molecular alterations across multiple brain regions. In this study, we applied an integrative systems-level framework combining multi-region transcriptomic analysis, protein-protein interaction (PPI) network topology, machine learning-based validation, and in silico approaches to identify robust and pharmacologically relevant molecular targets in AD. Gene expression data from four AD-related brain regions (entorhinal cortex, frontal cortex, hippocampus, and temporal cortex) were obtained from the GSE5281 dataset, yielding 467 genes consistently dysregulated across all regions. Network analysis identified a subset of downregulated hub genes predominantly associated with mitochondrial bioenergetics and proteostasis pathways. Intersection with experimentally curated targets of genistein and resveratrol prioritized four elite genes, COX5B, ENO1, HSP90AB1, and SDHB as shared and biologically central nodes. To assess the collective discriminative capacity of the identified gene set, a random forest classifier was trained using shared differentially expressed genes. The model demonstrated strong classification performance with a low out-of-bag error rate, while feature importance analysis identified SDHB as the most influential contributor, followed by COX5B and ENO1, indicating synergistic multigene effects rather than isolated biomarker behavior. Machine learning was applied as an integrative validation layer to reinforce biological relevance, rather than as a standalone diagnostic tool. Finally, molecular docking analyses revealed favorable binding affinities of genistein and resveratrol toward all four elite targets. Overall, these findings highlight a convergent mitochondrial-proteostasis dysfunction axis in AD and suggest COX5B, ENO1, HSP90AB1, and SDHB as promising multi-target nodes for polyphenol-based therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.